Is ADXS or EGRX more profitable?

Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Eagle Pharmaceuticals N/A N/A N/A

Do analysts prefer ATHE or EGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, ATHE or EGRX?

Eagle Pharmaceuticals has higher revenue and earnings than Alterity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Eagle Pharmaceuticals $257.55M 0.03 $35.64M $1.18 0.51

Is ATHE or EGRX more profitable?

Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Eagle Pharmaceuticals N/A N/A N/A

Do analysts recommend ABVC or EGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ABVC or EGRX more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -62.46% -39.99% Eagle Pharmaceuticals N/A N/A N/A

Do analysts rate EGRX or NNVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is EGRX or NNVC more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A NanoViricides N/A -87.90% -78.69%

Eagle Pharmaceuticals (EGRX) Competitors

$0.60 -0.01 (-1.64%)

As of 06/12/2026 03:42 PM Eastern

Compare

EGRX vs. ADXS, ATHE, ABVC, NNVC, and CPHI

Should you buy Eagle Pharmaceuticals stock or one of its competitors? MarketBeat compares Eagle Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eagle Pharmaceuticals include Ayala Pharmaceuticals (ADXS), Alterity Therapeutics (ATHE), ABVC BioPharma (ABVC), NanoViricides (NNVC), and China Pharma (CPHI). These companies are all part of the "pharmaceutical products" industry.

How does Eagle Pharmaceuticals compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Eagle Pharmaceuticals has higher revenue and earnings than Ayala Pharmaceuticals. Ayala Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.51

In the previous week, Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled Eagle Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Eagle Pharmaceuticals	Neutral

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Eagle Pharmaceuticals	N/A	N/A	N/A

Summary

Eagle Pharmaceuticals beats Ayala Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Alterity Therapeutics had 3 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 3 mentions for Alterity Therapeutics and 0 mentions for Eagle Pharmaceuticals. Alterity Therapeutics' average media sentiment score of 0.36 beat Eagle Pharmaceuticals' score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alterity Therapeutics	Neutral
Eagle Pharmaceuticals	Neutral

Alterity Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Eagle Pharmaceuticals has higher revenue and earnings than Alterity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.51

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Eagle Pharmaceuticals	N/A	N/A	N/A

Summary

Alterity Therapeutics beats Eagle Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eagle Pharmaceuticals' return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
Eagle Pharmaceuticals	N/A	N/A	N/A

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, ABVC BioPharma had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for ABVC BioPharma and 0 mentions for Eagle Pharmaceuticals. ABVC BioPharma's average media sentiment score of 1.31 beat Eagle Pharmaceuticals' score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ABVC BioPharma	Positive
Eagle Pharmaceuticals	Neutral

ABVC BioPharma has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Eagle Pharmaceuticals has higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	60.67	-$7.91M	-$0.40	N/A
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.51

Summary

Eagle Pharmaceuticals beats ABVC BioPharma on 9 of the 13 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to NanoViricides?

Eagle Pharmaceuticals (NASDAQ:EGRX) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Eagle Pharmaceuticals has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.51
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Eagle Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, NanoViricides' average media sentiment score of 0.23 beat Eagle Pharmaceuticals' score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
NanoViricides	Neutral

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 3.6% of NanoViricides shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Eagle Pharmaceuticals' return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
NanoViricides	N/A	-87.90%	-78.69%

Summary

Eagle Pharmaceuticals beats NanoViricides on 8 of the 12 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to China Pharma?

China Pharma (NYSE:CPHI) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

Eagle Pharmaceuticals has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. Eagle Pharmaceuticals' return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Eagle Pharmaceuticals	N/A	N/A	N/A

China Pharma has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

In the previous week, China Pharma's average media sentiment score of 0.32 beat Eagle Pharmaceuticals' score of 0.00 indicating that China Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
China Pharma	Neutral
Eagle Pharmaceuticals	Neutral

Eagle Pharmaceuticals has higher revenue and earnings than China Pharma. China Pharma is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	7.25	-$3.08M	-$0.55	N/A
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.51

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 6.4% of China Pharma shares are owned by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Eagle Pharmaceuticals beats China Pharma on 9 of the 12 factors compared between the two stocks.

Get Eagle Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EGRX vs. The Competition

Export

Metric	Eagle Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.79M	$981.41M	$6.75B	$12.02B
Dividend Yield	N/A	4.84%	2.66%	5.61%
P/E Ratio	0.51	1.45	23.82	24.42
Price / Sales	0.03	126.92	510.69	109.73
Price / Cash	0.40	20.06	44.01	55.64
Price / Book	N/A	7.85	10.66	6.79
Net Income	$35.64M	-$4.88M	$3.57B	$337.66M
7 Day Performance	N/A	0.44%	0.87%	2.56%
1 Month Performance	60.00%	-0.06%	0.18%	2.03%
1 Year Performance	-75.00%	46.38%	25.23%	30.31%

Eagle Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EGRX Eagle Pharmaceuticals	N/A	$0.60 -1.6%	N/A	-74.5%	$7.79M	$257.55M	0.51	100	Gap Down High Trading Volume
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
ATHE Alterity Therapeutics	0.7207 of 5 stars	$4.01 -0.1%	N/A	-8.3%	$35.61M	N/A	N/A	10	Gap Down
ABVC ABVC BioPharma	1.1344 of 5 stars	$1.25 -8.1%	N/A	-35.7%	$35.36M	$510K	N/A	30	Positive News
NNVC NanoViricides	0.3734 of 5 stars	$1.61 -4.5%	N/A	-19.2%	$34.74M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EGRX) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. ADXS, ATHE, ABVC, NNVC, and CPHI

How does Eagle Pharmaceuticals compare to Ayala Pharmaceuticals?

Summary

How does Eagle Pharmaceuticals compare to Alterity Therapeutics?

Summary

How does Eagle Pharmaceuticals compare to ABVC BioPharma?

Summary

How does Eagle Pharmaceuticals compare to NanoViricides?

Summary

How does Eagle Pharmaceuticals compare to China Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. ADXS, ATHE, ABVC, NNVC, and CPHI

How does Eagle Pharmaceuticals compare to Ayala Pharmaceuticals?

Which has preferable valuation and earnings, ADXS or EGRX?

Does the media refer more to ADXS or EGRX?

Do insiders and institutionals have more ownership in ADXS or EGRX?

Which has more volatility & risk, ADXS or EGRX?

Is ADXS or EGRX more profitable?

Summary

How does Eagle Pharmaceuticals compare to Alterity Therapeutics?

Do analysts prefer ATHE or EGRX?

Does the media refer more to ATHE or EGRX?

Which has more volatility & risk, ATHE or EGRX?

Do insiders and institutionals hold more shares of ATHE or EGRX?

Which has higher valuation and earnings, ATHE or EGRX?

Is ATHE or EGRX more profitable?

Summary

How does Eagle Pharmaceuticals compare to ABVC BioPharma?

Do analysts recommend ABVC or EGRX?

Is ABVC or EGRX more profitable?

Do insiders & institutionals hold more shares of ABVC or EGRX?

Does the media prefer ABVC or EGRX?

Which has more risk & volatility, ABVC or EGRX?

Which has stronger earnings and valuation, ABVC or EGRX?

Summary

How does Eagle Pharmaceuticals compare to NanoViricides?

Which has higher earnings and valuation, EGRX or NNVC?

Which has more volatility and risk, EGRX or NNVC?

Do analysts rate EGRX or NNVC?

Does the media favor EGRX or NNVC?

Do institutionals and insiders hold more shares of EGRX or NNVC?

Is EGRX or NNVC more profitable?

Summary

How does Eagle Pharmaceuticals compare to China Pharma?

Is CPHI or EGRX more profitable?

Which has more risk & volatility, CPHI or EGRX?

Does the media prefer CPHI or EGRX?

Which has preferable earnings and valuation, CPHI or EGRX?

Do insiders and institutionals hold more shares of CPHI or EGRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools